Additionally, with the discovery of commonly expressed molecular targets in bladder cancer, targeted therapies have been developed, such as antibody–drug conjugates of HER2 and fibroblast growth factor receptor inhibitors. Here, ERBB2 is linked to urinary bladder carcinoma.